Jason Harris

Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Brentuximab vedotin (Adcetris) has been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

An analysis of results from 5 clinical trials showed that circulating tumor cell (CTC) conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer.

By combining data from genome-wide association studies with epidemiological surveys, investigators say they have developed a genetic tool that can predict age of onset for aggressive prostate cancer.

The European Commission has approved the bevacizumab biosimilar ABP 215, for the treatment of patients across several tumor types.

Adding tumor-treating fields to temozolomide resulted in improved progression-free survival and overall survival for patients with glioblastoma.

The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.

Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.

Men with newly diagnosed mCRPC in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overallHR-QOL following treatment with abiraterone acetate plus prednisone.

Neoadjuvant chemoradiotherapy did not lower postoperative health-related quality of life compared with surgery alone for patients with esophageal or junctional cancer.

Children with TP53 pathogenic variants were more likely to both develop acute lymphoblastic leukemia, as well as secondary cancers later on, according to a recent analysis.

TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

The FDA has granted a breakthrough therapy designation to eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia.

Nearly 7 in 10 patients with locally advanced or metastatic BRAF V600E–mutated anaplastic thyroid cancer responded to treatment with the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).

Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.

In patients with stage III favorable-histology Wilms tumor, negative nodal involvement and the absence of loss of heterozygosity at chromosomes 1p and 16q were predictors for event-free survival and overall survival.

Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.

The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.

Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.

The United Kingdom's National Institute for Health and Care Excellence has issued guidance supporting approval for ribociclib and palbociclib for patients with hormone receptor-positive/HER2-negative locally advanced or secondary breast cancer.

Loxo Oncology has initiated a rolling submission of data for a NDA to the FDA for the novel pan-TRK inhibitor larotrectinib (LOXO-101) as a treatment for adult and pediatric patients with TRK fusion-positive advanced solid tumors.

Use of both a Pap smear and an HPV test did not identify more cervical cancers than HPV testing alone.

The United Kingdom's National Institute for Health and Care Excellence has issued guidance recommending ixazomib in for patients with relapsed/refractory multiple myeloma.

Persistent HPV 16/18 infection correlated with higher locoregional relapse, overall relapse, and was also associated with early relapses in women with locally advanced cervical cancers treated with radical radiochemotherapy.

The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.

Ten-year follow-up results from the StiL NHL1 study showed that frontline bendamustine (Treanda) plus rituximab (Rituxan) improved time-to-next-treatment compared with CHOP-R in patients with indolent lymphomas.